Francesco Dotta

List of Publications by Year in Descending Order

202 papers	9,645 citations	46 h-index	94 g-index
227 ext. papers	11,236 ext. citations	6.7 avg, IF	5.59 L-index

#	Paper	IF	Citations
202	Environmental Factors in the Development of Diabetes Mellitus. *Sustainable Development Goals Series*, **2022**, 275-317	0.5	
201	Increased Expression of Viral Sensor MDA5 in Pancreatic Islets and in Hormone-Negative Endocrine Cells in Recent Onset Type 1 Diabetic Donors.. *Frontiers in Immunology*, **2022**, 13, 833141	8.4	0
200	Identification and Validation of miR-222-3p and miR-409-3p as Plasma Biomarkers in Gestational Diabetes Mellitus Sharing Validated Target Genes Involved in Metabolic Homeostasis.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	2
199	NF-B-inducing kinase (NIK) is activated in pancreatic cells but does not contribute to the development of diabetes.. *Cell Death and Disease*, **2022**, 13, 476	9.8	0
198	Prognostic bioindicators in severe COVID-19 patients. *Cytokine*, **2021**, 141, 155455	4	13
197	Extracellular Vesicles in Immune System Regulation and Type 1 Diabetes: Cell-to-Cell Communication Mediators, Disease Biomarkers, and Promising Therapeutic Tools. *Frontiers in Immunology*, **2021**, 12, 682948	8.4	2
196	Non-Coding RNAs: Novel Players in Insulin Resistance and Related Diseases. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
195	The Landscape of microRNAs in Cell: Between Phenotype Maintenance and Protection. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
194	Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. *Scandinavian Journal of Immunology*, **2021**, 94, e13031	3.4	7
193	Circulating microRNAs Signature for Predicting Response to GLP1-RA Therapy in Type 2 Diabetic Patients: A Pilot Study. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
192	Immunoregulated insulitis and slow-progressing type 1 diabetes after duodenopancreatectomy. *Diabetologia*, **2021**, 64, 2731-2740	10.3	0
191	Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples. *STAR Protocols*, **2021**, 2, 100606	1.4	3
190	CD8 T Cells Variably Recognize Native Versus Citrullinated GRP78 Epitopes in Type 1 Diabetes. *Diabetes*, **2021**, 70, 2879-2891	0.9	2
189	Prevention and treatment of autoimmune diseases with plant virus nanoparticles. *Science Advances* , **2020**, 6, eaaz0295	14.3	10
188	Intestinal Delivery of Proinsulin and IL-10 via Combined With Low-Dose Anti-CD3 Restores Tolerance Outside the Window of Acute Type 1 Diabetes Diagnosis. *Frontiers in Immunology*, **2020**, 11, 1103	8.4	3
187	Dual energy CT in gland tumors: a comprehensive narrative review and differential diagnosis. *Gland Surgery*, **2020**, 9, 2269-2282	2.2	3
186	1795-P: Proinsulin-Insulin Pancreatic Islets In-situ Expression Mirrors Metabolic Defects Observed in Type 2 Diabetic and Glucose Intolerant Living Donors. *Diabetes*, **2020**, 69, 1795-P	0.9	

185	miR-409-3p is reduced in plasma and islet immune infiltrates of NOD diabetic mice and is differentially expressed in people with type 1 diabetes. *Diabetologia*, **2020**, 63, 124-136	10.3	12
184	From immunohistological to anatomical alterations of human pancreas in type 1 diabetes: New concepts on the stage. *Diabetes/Metabolism Research and Reviews*, **2020**, 36, e3264	7.5	9
183	MicroRNA Expression in the Aqueous Humor of Patients with Diabetic Macular Edema. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
182	Pancreatic Alpha-Cells Contribute Together With Beta-Cells to CXCL10 Expression in Type 1 Diabetes. *Frontiers in Endocrinology*, **2020**, 11, 630	5.7	7
181	SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic -Cells and in the Human Pancreas Microvasculature. *Frontiers in Endocrinology*, **2020**, 11, 596898	5.7	72
180	Is resistant hypertension an independent predictor of all-cause mortality in individuals with type 2 diabetes? A prospective cohort study. *BMC Medicine*, **2019**, 17, 83	11.4	4
179	Fostering improved human islet research: a European perspective. *Diabetologia*, **2019**, 62, 1514-1516	10.3	9
178	Molecular Dysfunction and Phenotypic Derangement in Diabetic Cardiomyopathy. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	47
177	Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	19
176	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. *Acta Diabetologica*, **2019**, 56, 605-617	3.9	29
175	Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic Cell Death and May Contribute to Type 1 Diabetes Development. *Cell Metabolism*, **2019**, 29, 348-361.e6	24.6	119
174	Islet-reactive CD8 T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. *Science Immunology*, **2018**, 3,	28	98
173	G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2018**, 32, 201-213	6.5	7
172	Circulating MicroRNAs as Biomarkers of Gestational Diabetes Mellitus: Updates and Perspectives. *International Journal of Endocrinology*, **2018**, 2018, 6380463	2.7	31
171	Circulating MicroRNAs in Elderly Type 2 Diabetic Patients. *International Journal of Endocrinology*, **2018**, 2018, 6872635	2.7	20
170	Conventional and Neo-antigenic Peptides Presented by Cells Are Targeted by Circulating Na e CD8+ T Cells in Type 1 Diabetic and Healthy Donors. *Cell Metabolism*, **2018**, 28, 946-960.e6	24.6	104
169	Unexpected subcellular distribution of a specific isoform of the Coxsackie and adenovirus receptor, CAR-SIV, in human pancreatic beta cells. *Diabetologia*, **2018**, 61, 2344-2355	10.3	31
168	MicroRNA Expression Analysis of In Vitro Dedifferentiated Human Pancreatic Islet Cells Reveals the Activation of the Pluripotency-Related MicroRNA Cluster miR-302s. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	11

167	Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes. *Endocrine*, **2018**, 62, 263-266	4	2
166	Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. *JCI Insight*, **2018**, 3,	9.9	50
165	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. *Diabetes Care*, **2018**, 41, 258-266	14.6	208
164	MicroRNAs as Regulators of Insulin Signaling: Research Updates and Potential Therapeutic Perspectives in Type 2 Diabetes. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	38
163	Acute on chronic limb ischemia: From surgical embolectomy and thrombolysis to endovascular options. *Seminars in Vascular Surgery*, **2018**, 31, 66-75	1.2	9
162	Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. *Non-coding RNA*, **2018**, 4,	7.1	26
161	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet, The*, **2018**, 392, 1519-1529	40	771
160	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. *Diabetes Care*, **2018**, 41, 2552-2559	14.6	109
159	MicroRNAs: markers of β cell stress and autoimmunity. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2018**, 25, 237-245	4	13
158	Circulating microRNAs and diabetes mellitus: a novel tool for disease prediction, diagnosis, and staging?. *Journal of Endocrinological Investigation*, **2017**, 40, 591-610	5.2	55
157	Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. *Diabetes and Metabolism*, **2017**, 43, 512-520	5.4	40
156	MicroRNA expression profiles of human iPSCs differentiation into insulin-producing cells. *Acta Diabetologica*, **2017**, 54, 265-281	3.9	27
155	Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 1089-1097	4.5	19
154	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 864-876	18.1	174
153	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 887-897	18.1	154
152	Regulatory T-cells from pancreatic lymphnodes of patients with type-1 diabetes express increased levels of microRNA miR-125a-5p that limits CCR2 expression. *Scientific Reports*, **2017**, 7, 6897	4.9	34
151	Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10-Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells. *Diabetes*, **2017**, 66, 448-459	0.9	46
150	MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p Regulate the Expression of Proapoptotic BH3-Only Proteins DP5 and PUMA in Human Pancreatic β Cells. *Diabetes*, **2017**, 66, 100-112	0.9	69

149	Circulating microRNA (miRNA) Expression Profiling in Plasma of Patients with Gestational Diabetes Mellitus Reveals Upregulation of miRNA miR-330-3p. *Frontiers in Endocrinology*, **2017**, 8, 345	5.7	49
148	Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, in situ hybridization and PCR to detect Coxsackievirus B1 in A549 cells. *Journal of Clinical Virology*, **2016**, 77, 21-8	14.5	18
147	Erectile dysfunction and diabetes: Association with the impairment of lipid metabolism and oxidative stress. *Clinical Biochemistry*, **2016**, 49, 70-8	3.5	6
146	Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3). *Diabetes Research and Clinical Practice*, **2016**, 120, S51	7.4	5
145	Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER after 56 Weeks in Subjects with Type 2 Diabetes (SUSTAIN 3). *Canadian Journal of Diabetes*, **2016**, 40, S41	2.1	3
144	The social burden of hypoglycemia in the elderly. *Acta Diabetologica*, **2015**, 52, 677-85	3.9	31
143	Human induced pluripotent stem cells differentiate into insulin-producing cells able to engraft in vivo. *Acta Diabetologica*, **2015**, 52, 1025-35	3.9	32
142	Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study. *Diabetes, Obesity and Metabolism*, **2015**, 17, 689-98	6.7	3
141	Towards an Earlier and Timely Diagnosis of Type 1 Diabetes: Is it Time to Change Criteria to Define Disease Onset?. *Current Diabetes Reports*, **2015**, 15, 115	5.6	9
140	Mast cells infiltrate pancreatic islets in human type 1 diabetes. *Diabetologia*, **2015**, 58, 2554-62	10.3	35
139	MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. *Acta Diabetologica*, **2015**, 52, 523-30	3.9	102
138	Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. *Cardiovascular Diabetology*, **2015**, 14, 116	8.7	36
137	MicroRNAs: Novel Players in the Dialogue between Pancreatic Islets and Immune System in Autoimmune Diabetes. *BioMed Research International*, **2015**, 2015, 749734	3	42
136	Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. *Diabetes Care*, **2015**, 38, 513-20	14.6	23
135	IL-17A increases the expression of proinflammatory chemokines in human pancreatic islets. *Diabetologia*, **2014**, 57, 502-11	10.3	39
134	Circulating miRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, 4190-8	5.6	45
133	Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. *Diabetes*, **2014**, 63, 2876-87	0.9	103
132	Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. *Acta Diabetologica*, **2014**, 51, 675-8	3.9	8

131	Enteroviral infections and development of type 1 diabetes: The Brothers Karamazov within the CVBs. *Diabetes*, **2014**, 63, 384-6	0.9	8
130	Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. *Diabetes*, **2014**, 63, 2026-36	0.9	53
129	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled study--the D.A.N.T.E (Diabetic ulcer Antimicrobial New Topical treatment Evaluation) study. *Acta Diabetologica*, **2014**, 51, 435-40	3.9	38
128	Coxsackieviruses and Insulitis **2013**, 157-166		
127	The year in immune intervention for type 1 diabetes. *Diabetes Technology and Therapeutics*, **2013**, 15 Suppl 1, S88-95	8.1	5
126	Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. *Diabetes*, **2013**, 62, 2072-7	7.9	140
125	Beyond glycemic control in diabetes mellitus: effects of incretin-based therapies on bone metabolism. *Frontiers in Endocrinology*, **2013**, 4, 73	5.7	25
124	Endocrine actions of osteocalcin. *International Journal of Endocrinology*, **2013**, 2013, 846480	2.7	84
123	The case for virus-induced type 1 diabetes. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2013**, 20, 292-8	4	21
122	Incretin hormones and beta-cell mass expansion: what we know and what is missing?. *Archives of Physiology and Biochemistry*, **2013**, 119, 161-9	2.2	11
121	MicroRNA profiling in sera of patients with type 2 diabetes mellitus reveals an upregulation of miR-31 expression in subjects with microvascular complications. *Journal of Biomedical Science and Engineering*, **2013**, 06, 58-64	0.7	15
120	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. *Lancet, The*, **2012**, 379, 2270-8	40	125
119	A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. *Diabetologia*, **2012**, 55, 3262-72	10.3	175
118	Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, 1737-44	5.6	183
117	In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. *Acta Diabetologica*, **2012**, 49 Suppl 1, S123-31	3.9	6
116	Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus. *Expert Opinion on Pharmacotherapy*, **2012**, 13, 1377-84	4	11
115	Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. *Clinical and Experimental Immunology*, **2012**, 168, 24-9	6.2	23
114	In type 1 diabetes immunocompetent cells are defective in IL-16 secretion. *Scandinavian Journal of Immunology*, **2012**, 75, 127-8	3.4	1

113	Viral infections and diabetes. *Advances in Experimental Medicine and Biology*, **2012**, 771, 252-71	3.6	22
112	Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. *Journal of Experimental Medicine*, **2012**, 209, 51-60	16.6	448
111	Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. *Journal of Clinical Investigation*, **2012**, 122, 1717-25	15.9	136
110	Detection of four diabetes specific autoantibodies in a single radioimmunoassay: an innovative high-throughput approach for autoimmune diabetes screening. *Clinical and Experimental Immunology*, **2011**, 166, 317-24	6.2	20
109	MicroRNAs as new tools for exploring type 1 diabetes: relevance for immunomodulation and transplantation therapy. *Transplantation Proceedings*, **2011**, 43, 330-2	1.1	8
108	Measuring adrenal autoantibody response: interlaboratory concordance in the first international serum exchange for the determination of 21-hydroxylase autoantibodies. *Clinical Immunology*, **2011** , 140, 291-9	9	23
107	Innate immunity and the pathogenesis of type 1 diabetes. *Seminars in Immunopathology*, **2011**, 33, 57-66	12	35
106	Delta-cell-specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. *Diabetes/Metabolism Research and Reviews*, **2011**, 27, 755-60	7.5	7
105	Increased expression of microRNA miR-326 in type 1 diabetic patients with ongoing islet autoimmunity. *Diabetes/Metabolism Research and Reviews*, **2011**, 27, 862-6	7.5	95
104	Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 2010;59:2862-2871. *Diabetes*, **2011**, 60, e12; author reply e13	0.9	2
103	Histopathology and ex vivo insulin secretion of pancreatic islets in gestational diabetes: A case report. *Islets*, **2011**, 3, 231-3	2	8
102	Islet inflammation and CXCL10 in recent-onset type 1 diabetes. *Clinical and Experimental Immunology*, **2010**, 159, 338-43	6.2	123
101	Serum transforming growth factor 1 during diabetes development in non-obese diabetic mice and humans. *Clinical and Experimental Immunology*, **2010**, 162, 407-14	6.2	9
100	Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al. *Diabetes, Obesity and Metabolism*, **2010**, 12, 1127-8	6.7	8
99	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. *European Journal of Endocrinology*, **2010**, 162, 361-9	6.5	33
98	Mechanisms of impaired bone strength in type 1 and 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 683-90	4.5	79
97	Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. *Diabetologia*, **2010**, 53, 1395-405	10.3	168
96	Virus infections: lessons from pancreas histology. *Current Diabetes Reports*, **2010**, 10, 357-61	5.6	13

95	GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. *Clinical Immunology*, **2009**, 131, 271-6	9	3
94	Diagnosis and approach to posttransplant diabetes. *Current Diabetes Reports*, **2009**, 9, 317-23	5.6	4
93	Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes, Obesity and Metabolism*, **2009**, 11, 589-95	6.7	89
92	Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. *Diabetes, Obesity and Metabolism*, **2009**, 11, 506-15	6.7	147
91	An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. *Regulatory Peptides*, **2008**, 146, 4-11		81
90	Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. *Transplantation Proceedings*, **2008**, 40, 1888-90	1.1	32
89	Incretine e funzione insulare: fisiopatologia. *L Endocrinologo*, **2008**, 9, 155-162	0	
88	Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. *Annals of Clinical Biochemistry*, **2008**, 45, 218-20	2.2	5
87	Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. *Diabetes*, **2008**, 57, 1276-83	0.9	42
86	POST TRANSPLANTATION DIABETES MELLITUS: ROLE OF INSULIN-RESISTANCE AND PRO-INFLAMMATORY CYTOKINES IN FIRST YEAR POST-TRANSPLANT. *Transplantation*, **2008**, 86, 275	1.8	
85	Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes, Obesity and Metabolism*, **2008**, 10, 82-90	6.7	135
84	Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. *Diabetologia*, **2008**, 51, 1296-305	10.3	97
83	Can NK cells be a therapeutic target in human type 1 diabetes?. *European Journal of Immunology*, **2008**, 38, 2961-3	6.1	18
82	Hedgehog signaling during expansion of human pancreatic islet-derived precursors. *Annals of the New York Academy of Sciences*, **2008**, 1150, 43-5	6.5	2
81	Generation and expansion of multipotent mesenchymal progenitor cells from cultured human pancreatic islets. *Cell Death and Differentiation*, **2007**, 14, 1860-71	12.7	78
80	Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 5115-20	11.5	441
79	High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. *Diabetes Care*, **2007**, 30, 932-8	14.6	160
78	Type VII collagen in Alport syndrome. *Nephrology Dialysis Transplantation*, **2007**, 22, 3501-7	4.3	2

77	Evidence of a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: a new tool to distinguish disease-specific immunoreactivities. *Clinical Immunology*, **2006**, 121, 40-6	9	4
76	Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 5064-8	5.6	22
75	CD4+CD25high regulatory T cells in human autoimmune diabetes. *Journal of Autoimmunity*, **2005**, 24, 55-62	15.5	162
74	IA-2 combined epitope assay: a new, highly sensitive approach to evaluate IA-2 humoral autoimmunity in type 1 diabetes. *Clinical Immunology*, **2005**, 115, 260-7	9	14
73	Guidelines for the treatment and management of new-onset diabetes after transplantation. *Clinical Transplantation*, **2005**, 19, 291-8	3.8	203
72	Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. *Diabetologia*, **2005**, 48, 1565-75	10.3	267
71	Latent autoimmune diabetes in adults (LADA) should be less latent. *Diabetologia*, **2005**, 48, 2206-12	10.3	232
70	Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus. *European Journal of Endocrinology*, **2005**, 152, 119-25	6.5	19
69	Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. *European Journal of Endocrinology*, **2005**, 152, 485-9	6.5	25
68	The acquisition of an insulin-secreting phenotype by HGF-treated rat pancreatic ductal cells (ARIP) is associated with the development of susceptibility to cytokine-induced apoptosis. *Journal of Molecular Endocrinology*, **2005**, 34, 367-76	4.5	9
67	Type 1 diabetes mellitus as a polygenic multifactorial disease: immunopathogenic mechanisms of beta-cell destruction. *Acta Biomedica*, **2005**, 76 Suppl 3, 14-8	3.2	4
66	Italian addison network study: update of diagnostic criteria for the etiological classification of primary adrenal insufficiency. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1598-604	5.6	72
65	The role of peripheral benzodiazepine receptors on the function and survival of isolated human pancreatic islets. *European Journal of Endocrinology*, **2004**, 151, 207-14	6.5	20
64	Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients. *Diabetes/Metabolism Research and Reviews*, **2004**, 20, 246-51	7.5	19
63	Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death. *Journal of Cellular Physiology*, **2004**, 200, 177-200	7	81
62	Pathological changes in human insulitis. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2004**, 11, 82-84		
61	New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. *Transplantation*, **2003**, 75, SS3-24	1.8	459
60	Celiac disease-associated transglutaminase autoantibody target domains at diagnosis are age and sex dependent. *Clinical Immunology*, **2003**, 109, 318-24	9	6

59	Application of phage display peptide library to autoimmune diabetes: identification of IA-2/ICA512bdc dominant autoantigenic epitopes. *European Journal of Immunology*, **2002**, 32, 1420-7	6.1	15
58	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. *Journal of Cellular Biochemistry*, **2002**, 84, 636-644	4.7	28
57	Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. *Diabetes*, **2002**, 51, 1437-42	0.9	501
56	ICA512(IA-2) epitope specific assays distinguish transient from diabetes associated autoantibodies. *Journal of Autoimmunity*, **2002**, 18, 191-6	15.5	9
55	Neonatal syndromes of polyendocrinopathy. *Endocrinology and Metabolism Clinics of North America*, **2002**, 31, 283-93, v	5.5	5
54	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets **2002**, 84, 636		1
53	Upregulation of mitochondrial peripheral benzodiazepine receptor expression by cytokine-induced damage of human pancreatic islets. *Journal of Cellular Biochemistry*, **2002**, 84, 636-44	4.7	8
52	Bovine islets are less susceptible than human islets to damage by human cytokines. *Transplantation* , **2001**, 71, 21-6	1.8	19
51	Th2 cytokines have a partial, direct protective effect on the function and survival of isolated human islets exposed to combined proinflammatory and Th1 cytokines. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 4974-8	5.6	43
50	Autoantibody negative new onset type 1 diabetic patients lacking high risk HLA alleles in a caucasian population: are these type 1b diabetes cases?. *Diabetes/Metabolism Research and Reviews* , **2000**, 16, 8-14	7.5	13
49	Effects of prolonged exposure to pancreatic glucagon on the function, antigenicity and survival of isolated human islets. *Diabetes/Metabolism Research and Reviews*, **2000**, 16, 281-6	7.5	5
48	Function of pancreatic islets isolated from a type 1 diabetic patient. *Diabetes Care*, **2000**, 23, 701-3	14.6	37
47	Congenital autoimmune diabetes mellitus. *New England Journal of Medicine*, **2000**, 342, 1529-31	59.2	12
46	Presence of interleukin 4 or interleukin 10, but not both cytokines, in pancreatic tissue of two patients with recently diagnosed diabetes mellitus type I. *Autoimmunity*, **2000**, 32, 161-6	3	6
45	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type 1b diabetes cases? **2000**, 16, 8		2
44	Insulin prophylaxis down-regulates islet antigen expression and islet autoimmunity in the low-dose Stz mouse model of diabetes. *Autoimmunity*, **1999**, 29, 249-56	3	3
43	T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus. *European Journal of Endocrinology*, **1999**, 141, 272-8	6.5	12
42	Expression of Reg and cytokeratin 20 during ductal cell differentiation and proliferation in a mouse model of autoimmune diabetes. *European Journal of Endocrinology*, **1999**, 141, 644-52	6.5	42

41	The GM2-1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granules and is not beta-cell specific. *Endocrinology*, **1998**, 139, 316-9	4.8	16
40	Autoantibodies to the GM2-1 islet ganglioside and to GAD-65 at type 1 diabetes onset. *Journal of Autoimmunity*, **1997**, 10, 585-8	15.5	19
39	Identification of a novel type 1 diabetes-specific epitope by screening phage libraries with sera from pre-diabetic patients. *Journal of Molecular Biology*, **1997**, 268, 599-606	6.5	20
38	A new solid-phase radioimmunoassay to detect anti-GAD65 autoantibodies. *Journal of Immunological Methods*, **1997**, 207, 107-13	2.5	2
37	Gangliosides and autoimmune diabetes. *Diabetes/metabolism Reviews*, **1997**, 13, 163-79		33
36	Gangliosides and autoimmune diabetes **1997**, 13, 163		1
35	Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. *Diabetes*, **1996**, 45, 1193-6	0.9	27
34	Selection of phage-displayed peptides mimicking type 1 diabetes-specific epitopes. *Journal of Autoimmunity*, **1996**, 9, 431-6	15.5	17
33	Antigenic determinants in type 1 diabetes mellitus. Review article. *Apmis*, **1996**, 104, 769-74	3.4	8
32	Beta-cell markers and autoantigen expression by a human insulinoma cell line: similarities to native beta cells. *Journal of Endocrinology*, **1996**, 150, 113-20	4.7	18
31	The use of immunological markers in IDDM after more than 20 years from ICA description. *Diabetes/metabolism Reviews*, **1996**, 12, 121-6		1
30	Autoimmunity to the GM2-1 islet ganglioside before and at the onset of type I diabetes. *Diabetes*, **1996**, 45, 1193-1196	0.9	10
29	GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. *Diabetologia*, **1995**, 38, 1117-21	10.3	29
28	Anti-ganglioside antibodies in new onset type 1 diabetic patients and high risk subjects. *Autoimmunity*, **1995**, 22, 43-8	3	11
27	GM2-1 pancreatic islet ganglioside: identification and characterization of a novel islet-specific molecule. *Diabetologia*, **1995**, 38, 1117-1121	10.3	
26	Autoantigens in type 1 diabetes mellitus. *Journal of Endocrinological Investigation*, **1994**, 17, 497-508	5.2	2
25	Rat pancreatic ganglioside expression: differences between a model of autoimmune islet B cell destruction and a normal strain. *Clinical Immunology and Immunopathology*, **1993**, 66, 143-9		15
24	Pancreatic gangliosides delay the onset of insulitis and hyperglycaemia in the low-dose streptozotocin mouse model. *Scandinavian Journal of Immunology*, **1993**, 37, 308-13	3.4	1

23	Modulation of antigen expression in relation to intervention strategies in type 1 diabetes. *Diabetes/metabolism Reviews*, **1993**, 9, 245-9		6
22	Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction. *Endocrinology*, **1992**, 130, 37-42	4.8	19
21	Autoimmune syndromes in major histocompatibility complex (MHC) congenic strains of nonobese diabetic (NOD) mice. The NOD MHC is dominant for insulitis and cyclophosphamide-induced diabetes. *Journal of Experimental Medicine*, **1992**, 176, 67-77	16.6	150
20	Autoantigens in thyroid and islet autoimmunity: similarities and differences. *Autoimmunity*, **1992**, 12, 223-37	3	6
19	Determination of gangliosides by high-performance liquid chromatography with photodiode-array detection. *Journal of Chromatography A*, **1992**, 605, 221-225	4.5	23
18	Type I Diabetes as a Mendelian and Regulated Immune Process **1990**, 351-362		1
17	Ganglioside expression in human pancreatic islets. *Diabetes*, **1989**, 38, 1478-83	0.9	40
16	Type I diabetes mellitus: a predictable autoimmune disease with interindividual variation in the rate of beta cell destruction. *Clinical Immunology and Immunopathology*, **1989**, 50, S85-95		21
15	Ganglioside expression in human pancreatic islets. *Diabetes*, **1989**, 38, 1478-1483	0.9	8
14	A prozone phenomenon interferes in islet cell antibody detection: direct comparison of two methods in subjects at risk of diabetes and in insulin dependent diabetics at onset. *Journal of Autoimmunity*, **1988**, 1, 109-17	15.5	6
13	A novel neuroendocrine cell surface glycoprotein: identification, isolation, and initial characterization. *Endocrinology*, **1988**, 122, 1263-8	4.8	7
12	Circulating anti-immunoglobulin antibodies in recent-onset type I diabetic patients. *Diabetes*, **1988**, 37, 462-6	0.9	13
11	Circulating anti-immunoglobulin antibodies in recent-onset type I diabetic patients. *Diabetes*, **1988**, 37, 462-466	0.9	5
10	Assay for cytoplasmic islet cell antibodies using two-color immunofluorescence and rat pancreas. *Advances in Experimental Medicine and Biology*, **1988**, 246, 63-7	3.6	1
9	Expression of cytoplasmic islet cell antigens by rat pancreas. *Diabetes*, **1987**, 36, 982-5	0.9	32
8	Humoral and cellular immune abnormalities in neonates of diabetic mothers: any pathological role?. *Experimental and Clinical Endocrinology and Diabetes*, **1987**, 89, 333-9	2.3	4
7	Immunology in diabetic pregnancy: activated T cells in diabetic mothers and neonates. *Diabetologia* , **1987**, 30, 66-71	10.3	22
6	Expression of cytoplasmic islet cell antigens by rat pancreas. *Diabetes*, **1987**, 36, 982-985	0.9	9

5	Activated T cells in normal pregnant women and neonates. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **1986**, 23, 127-35	2.4	8
4	The autonomic innervation of the human greater saphenous vein. *Acta Histochemica*, **1983**, 72, 111-6	2	6
3	Pancreatic islet ganglioside expression in nonobese diabetic mice: comparison with C57BL/10 mice and changes after autoimmune beta-cell destruction.		5
2	SARS-CoV-2 receptor Angiotensin I-Converting Enzyme type 2 (ACE2) is expressed in human pancreatic Ecells and in the human pancreas microvasculature		6
1	Reduced miR-184-3p expression occurring in Type 2 diabetic pancreatic islets protects Ecells from lipotoxic and proinflammatory apoptosis via a CRTC1-dependent mechanism		2